The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Open accessAbstract
The persistence of latently infected cells in patients under combinatory antiretroviral therapy (cART) is a major hurdle to HIV-1 eradication. Strategies to purge these reservoirs are needed and activation of viral gene expression in latently infected cells is one promising strategy. Bromodomain and Extraterminal (BET) bromodomain inhibitors (BETi) are compounds able to reactivate latent proviruses in a positive transcription elongation factor b (P-TEFb)-dependent manner. In this study, we tested the reactivation potential of protein kinase C (PKC) agonists (prostratin, bryostatin-1 and ingenol-B), which are known to activate NF-κB signaling pathway as well as P-TEFb, used alone or in combination with P-TEFb-releasing agents (HMBA and BETi (JQ1, I-BET, I-BET151)). Using in vitro HIV-1 post-integration latency model cell lines of T-lymphoid and myeloid lineages, we demonstrated that PKC agonists and P-TEFb-releasing agents alone acted as potent latency-reversing agents (LRAs) and that their combinations led to synergistic activation of HIV-1 expression at the viral mRNA and protein levels. Mechanistically, combined treatments led to higher activations of P-TEFb and NF-κB than the corresponding individual drug treatments. Importantly, we observed in ex vivo cultures of CD8+-depleted PBMCs from 35 cART-treated HIV-1+ aviremic patients that the percentage of reactivated cultures following combinatory bryostatin-1+JQ1 treatment was identical to the percentage observed with anti-CD3+anti-CD28 antibodies positive control stimulation. Remarkably, in ex vivo cultures of resting CD4+ T cells isolated from 15 HIV-1+ cART-treated aviremic patients, the combinations bryostatin-1+JQ1 and ingenol-B+JQ1 released infectious viruses to levels similar to that obtained with the positive control stimulation. The potent effects of these two combination treatments were already detected 24 hours post-stimulation. These results constitute the first demonstration of LRA combinations exhibiting such a potent effect and represent a proof-of-concept for the co-administration of two different types of LRAs as a potential strategy to reduce the size of the latent HIV-1 reservoirs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1972 · Cited by 1,722
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Identification of host proteins required for HIV infection through a functional genomic screen
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1152725 · Cited by 1,449
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
Ho, Y.-C., Shan, L., Hosmane, N. N., Wang, J., Laskey, S. B., Rosenbloom, D. I. S., Lai, J., Blankson, J. N., Siliciano, J. D., & Siliciano, R. F. (2013) · Cell · doi:10.1016/j.cell.2013.09.020 · Cited by 1,405
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
Self-citationSpecific HIV integration sites are linked to clonal expansion and persistence of infected cells
Maldarelli, F., Wu, X., Su, L., Simonetti, F. R., Shao, W., Hill, S., Spindler, J., Ferris, A. L., Mellors, J. W., Kearney, M. F., et al. (2014) · Science · doi:10.1126/science.1254194 · Cited by 849
The Challenge of Viral Reservoirs in HIV-1 Infection
Blankson, J. N., Persaud, D., & Siliciano, R. F. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104024 · Cited by 627
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Deng, K., Pertea, M., Rongvaux, A., Wang, L., Durand, C. M., Ghiaur, G., Lai, J., McHugh, H. L., Hao, H., Zhang, H., et al. (2015) · Nature · doi:10.1038/nature14053 · Cited by 504
Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3489 · Cited by 488
Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression
Karn, J., & Stoltzfus, C. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006916 · Cited by 437
Belkina, A. C., Nikolajczyk, B. S., & Denis, G. V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202838 · Cited by 418
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Chun, T.-W., Davey, R. T., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J. I., & Fauci, A. S. (2000) · Nature Medicine · doi:10.1038/77481 · Cited by 404
Spina, C. A., Anderson, J., Archin, N. M., Bosque, A., Chan, J., Famiglietti, M., Greene, W. C., Kashuba, A., Lewin, S. R., Margolis, D. M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003834 · Cited by 403
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Sobhian, B., Laguette, N., Yatim, A., Nakamura, M., Levy, Y., Kiernan, R., & Benkirane, M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.04.012 · Cited by 381
HIV-1 transcription and latency: an update
Van Lint, C., Bouchat, S., & Marcello, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-67 · Cited by 338
Self-citationKulkosky, J., Culnan, D. M., Roman, J., Dornadula, G., Schnell, M., Boyd, M. R., & Pomerantz, R. J. (2001) · Blood · doi:10.1182/blood.v98.10.3006 · Cited by 329
Prostratin Antagonizes HIV Latency by Activating NF-κB
Williams, S. A., Chen, L.-F., Kwon, H., Fenard, D., Bisgrove, D., Verdin, E., & Greene, W. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402124200 · Cited by 318
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3613 · Cited by 314
Li, Z., Guo, J., Wu, Y., & Zhou, Q. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks976 · Cited by 301
Maldarelli, F., Wu, X., Su, L., Simonetti, F., Wells, D., Shao, W., Spindler, J., Ferris, A., Mellors, J., Kearney, M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000479721.09749.2d · Cited by 294
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., & Chen, L.-F. (2014) · Oncogene · doi:10.1038/onc.2013.179 · Cited by 259
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1
Banerjee, C., Archin, N., Michaels, D., Belkina, A. C., Denis, G. V., Bradner, J., Sebastiani, P., Margolis, D. M., & Montano, M. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0312165 · Cited by 256
Crowe, S., Zhu, T., & Muller, W. A. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0503204 · Cited by 251
Reactivation of Latent HIV-1 by Inhibition of BRD4
Zhu, J., Gaiha, G. D., John, S. P., Pertel, T., Chin, C. R., Gao, G., Qu, H., Walker, B. D., Elledge, S. J., & Brass, A. L. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.008 · Cited by 244
Reuse, S., Calao, M., Kabeya, K., Guiguen, A., Gatot, J.-S., Quivy, V., Vanhulle, C., Lamine, A., Vaira, D., Demonte, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006093 · Cited by 240
Self-citationBET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Boehm, D., Calvanese, V., Dar, R. D., Xing, S., Schroeder, S., Martins, L., Aull, K., Li, P.-C., Planelles, V., Bradner, J. E., et al. (2013) · Cell Cycle · doi:10.4161/cc.23309 · Cited by 235
Cillo, A. R., Sobolewski, M. D., Bosch, R. J., Fyne, E., Piatak, M., Coffin, J. M., & Mellors, J. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402873111 · Cited by 232
Mehla, R., Bivalkar-Mehla, S., Zhang, R., Handy, I., Albrecht, H., Giri, S., Nagarkatti, P., Nagarkatti, M., & Chauhan, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011160 · Cited by 227
Colin, L., & Van Lint, C. (2009) · Retrovirology · doi:10.1186/1742-4690-6-111 · Cited by 222
Self-citationHIV-1 Latency in Monocytes/Macrophages
Kumar, A., Abbas, W., & Herbein, G. (2014) · Viruses · doi:10.3390/v6041837 · Cited by 217
Screening for noise in gene expression identifies drug synergies
Dar, R. D., Hosmane, N. N., Arkin, M. R., Siliciano, R. F., & Weinberger, L. S. (2014) · Science · doi:10.1126/science.1250220 · Cited by 208
Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency
Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A., & Zack, J. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8118-8123.2002 · Cited by 208
HMBA Releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and Activates HIV Transcription
Contreras, X., Barboric, M., Lenasi, T., & Peterlin, B. M. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030146 · Cited by 206
Self-citationVéronique, A., Marie‐Laure, C., Stéphane, B., Marianne, B., Corinne, F., Kadidia, T., Marie‐Christine, A., Josiane, W., Christine, R., & for the French Pediatric Cohort Study ANRS—CO 01 Group (2009) · Journal of Medical Virology · doi:10.1002/jmv.21390 · Cited by 202
Spivak, A. M., Andrade, A., Eisele, E., Hoh, R., Bacchetti, P., Bumpus, N. N., Emad, F., Buckheit, R., McCance-Katz, E. F., Lai, J., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit813 · Cited by 200
Bartholomeeusen, K., Xiang, Y., Fujinaga, K., & Peterlin, B. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410746 · Cited by 197
Self-citationRegulation of Cyclin T1 and HIV-1 Replication by MicroRNAs in Resting CD4 + T Lymphocytes
Chiang, K., Sung, T.-L., & Rice, A. P. (2012) · Journal of Virology · doi:10.1128/jvi.05065-11 · Cited by 181
Bouchat, S., Gatot, J., Kabeya, K., Cardona, C., Colin, L., Herbein, G., Wit, S. D., Clumeck, N., Lambotte, O., Rouzioux, C., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835535f5 · Cited by 155
Self-citationA pervasive role of histone acetyltransferases and deacetylases in an NF-κB-signaling code
Calao, M., Burny, A., Quivy, V., Dekoninck, A., & Lint, C. M. V. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.04.015 · Cited by 146
Self-citationLong-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses
Lebwohl, M., Shumack, S. P., Gold, L. S., Melgaard, A. E., Larsson, T. P., & Tyring, S. K. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.2766 · Cited by 139
Budhiraja, S., Famiglietti, M., Bosque, A., Planelles, V., & Rice, A. P. (2012) · Journal of Virology · doi:10.1128/jvi.02413-12 · Cited by 131
Venkataraman, S., Alimova, I. N., Balakrishnan, I., Harris, P. S., Birks, D. K., Griesinger, A. M., Amani, V. M., Cristiano, B., Remke, M., Taylor, M. D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1659 · Cited by 119
Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Pérez, M., de Vinuesa, A. G., Sánchez‐Duffhues, G., Márquez, N., Bellido, M., Muñoz‐Fernández, M. Á., Moreno, S., Castor, T. P., Calzado, M. A., & Muñóz, E. (2010) · Current HIV Research · doi:10.2174/157016210793499312 · Cited by 116
Host hindrance to HIV-1 replication in monocytes and macrophages
Bergamaschi, A., & Pancino, G. (2010) · Retrovirology · doi:10.1186/1742-4690-7-31 · Cited by 112
Crowe, S. M., & Sonza, S. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.3.345 · Cited by 110
Marine natural products: Bryostatins in preclinical and clinical studies
Kollár, P., Rajchard, J., Balounová, Z., & Pazourek, J. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.804100 · Cited by 110
Gulakowski, R. J., McMahon, J. B., Buckheit, R. W., Gustafson, K. R., & Boyd, M. R. (1997) · Antiviral Research · doi:10.1016/s0166-3542(96)01004-2 · Cited by 106
Biancotto, A., Grivel, J., Gondois‐Rey, F., Bettendroffer, L., Vigne, R., Brown, S., Margolis, L. B., & Hirsch, I. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10507-10515.2004 · Cited by 103
Jiang, G., Mendes, É. A., Kaiser, P., Sankaran‐Walters, S., Tang, Y., Weber, M. G., MELCHER, G. P., Thompson, G. R., Tanuri, A., Pianowski, L. F., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000289 · Cited by 100
Self-citationCTIP2 is a negative regulator of P-TEFb
Cherrier, T., Douce, V. L., Eilebrecht, S., Riclet, R., Marban, C., Dequiedt, F., Goumon, Y., Paillart, J., Mericskay, M., Parlakian, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220136110 · Cited by 97
Self-citationMcNamara, R. P., McCann, J. L., Gudipaty, S. A., & D’Orso, I. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.003 · Cited by 95
Abreu, C. M., Price, S. L., Shirk, E. N., da Cunha, R. D., Pianowski, L. F., Clements, J. E., Tanuri, A., & Gama, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097257 · Cited by 91
Self-citationReactivation of latent HIV-1 by new semi-synthetic ingenol esters
José, D. P., Bartholomeeusen, K., da Cunha, R. D., Abreu, C. M., Gliński, J. A., da Costa, T. B. F., Rabay, A. F. M. B., Filho, L. F. P., Dudycz, L. W., Ranga, U., et al. (2014) · Virology · doi:10.1016/j.virol.2014.05.033 · Cited by 91
Self-citationBocklandt, S., Blumberg, P. M., & Hamer, D. H. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00034-2 · Cited by 85
Bartholomeeusen, K., Fujinaga, K., Xiang, Y., & Peterlin, B. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.464834 · Cited by 85
Self-citationSung, T.-L., & Rice, A. P. (2006) · Retrovirology · doi:10.1186/1742-4690-3-66 · Cited by 74
Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs
McKernan, L. N., Momjian, D., & Kulkosky, J. (2012) · Advances in Virology · doi:10.1155/2012/805347 · Cited by 72
Lewin, S. R., Kirihara, J., Sonza, S., Irving, L., MILLS, J. S., & Crowe, S. M. (1998) · AIDS · doi:10.1097/00002030-199807000-00008 · Cited by 71
Wires, E. S., Alvarez, D., Dobrowolski, C. N., Wang, Y., Morales, M., Karn, J., & Harvey, B. K. (2012) · Journal of NeuroVirology · doi:10.1007/s13365-012-0103-4 · Cited by 64
HIV-1 Replication and Latency Are Regulated by Translational Control of Cyclin T1
Hoque, M., Shamanna, R. A., Guan, D., Pe’ery, T., & Mathews, M. B. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.060 · Cited by 63
HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters
Eilebrecht, S., Douce, V. L., Riclet, R., Targat, B., Hallay, H., Driessche, B. V., Schwartz, C., Robette, G., Lint, C. M. V., Rohr, O., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku168 · Cited by 62
Self-citationLiu, P., Xiang, Y., Fujinaga, K., Bartholomeeusen, K., Nilson, K. A., Price, D. H., & Peterlin, B. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539015 · Cited by 56
Self-citationHezareh, M., Moukil, M. A., Szántó, I., Pondarzewski, M., Mouche, S., Cherix, N., Brown, S. J., Carpentier, J., & Foti, M. (2004) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020401500404 · Cited by 51
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant, S., Roberts, J. D., Poplin, E. A., Tombes, M. B., Kyle, B., Welch, D. G., Carr, M. A., & Bear, H. D. (1998) · PubMed · Cited by 51
PKC phosphorylates HEXIM1 and regulates P-TEFb activity
Fujinaga, K., Barborič, M., Li, Q., Luo, Z., Price, D. H., & Peterlin, B. M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks682 · Cited by 51
Self-citationMicroRNA-Mediated Restriction of HIV-1 in Resting CD4+ T Cells and Monocytes
Chiang, K., & Rice, A. P. (2012) · Viruses · doi:10.3390/v4091390 · Cited by 50
Morgan, R. J., Leong, L., Chow, W. A., Gandara, D. R., Frankel, P. H., García, A. A., Lenz, H., & Doroshow, J. H. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9557-5 · Cited by 44
Weitman, S. D., Langevin, A., Berkow, R. L., Thomas, P. J., Hurwitz, C. A., Kraft, A. S., Dubowy, R. L., Smith, D. L., & Bernstein, M. L. (1999) · PubMed · Cited by 35
Mbonye, U. R., Wang, B., Gokulrangan, G., Chance, M. R., & Karn, J. (2015) · PROTEOMICS · doi:10.1002/pmic.201500038 · Cited by 30
HIV Type 1 Abrogates TAP-Mediated Transport of Antigenic Peptides Presented by MHC Class I
Kutsch, O., Vey, T., Kerkau, T., Hünig, T., & Schimpl, A. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202320886361 · Cited by 22
Cited by
Microglial Cells: The Main HIV-1 Reservoir in the Brain
Wallet, C., De Rovere, M., Van Assche, J., Daouad, F., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Van Lint, C., Rohr, O., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00362 · Cited by 368
Self-citationTargeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Ait-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Rohr, O., & Van Lint, C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03060 · Cited by 163
Self-citationLatency Reversing Agents and the Road to an HIV Cure
Tioka, L., Diez, R. C., Sönnerborg, A., & van de Klundert, M. (2025) · Pathogens · doi:10.3390/pathogens14030232 · Cited by 20
Metadata
- Authors
- Darcis, G., Kula, A., Bouchat, S., Fujinaga, K., Corazza, F., Ait-Ammar, A., Delacourt, N., Melard, A., Kabeya, K., Vanhulle, C., Van Driessche, B., Gatot, J.-S., Cherrier, T., Pianowski, L. F., Gama, L., Schwartz, C., Vila, J., Burny, A., Clumeck, N., Moutschen, M., De Wit, S., Peterlin, B. M., Rouzioux, C., Rohr, O., & Van Lint, C.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-30
- Volume
- 11
- Issue
- 7
- Pages
- e1005063
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1889176404
- Cited by
- 281
- References
- 74
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.